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Towards a Typology of Business 
Models in the Biotechnology Industry 
 
Abstract 
 
The purpose of this paper is to identify a selection of key business models 
- “typology” -  applied in the biotechnology industry.  The focus is on the 
differences between traditional/closed or stand-alone business models 
opposed to open or networked business models.  
 
A number of illustrative case studies and good practices are presented to 
show that new biotechnology firms are gradually adopting a “best of both 
worlds” strategy, with both closed business models and open, networked 
models as a way for gaining access to the market, in close collaboration 
with large global pharmaceutical companies.  The case firms and good 
practices are taken from a recent country study for Belgium. 
 
Introduction 
 
Biotechnology is developing in several forms such as bioclusters and 
bioRegions, i.e. regional clusters of life science activities and networks.   
A bioRegion is defined by the definition of the European Commission 
(PwC, 2011; Zechendorf, 2008; 2011): “Any geographically meaningful 
entity which can, but has not necessarily, to be a political or administrative 
entity for which the promotion of biotech and/or life sciences has been 
defined as a priority. 
 
The global biotechnology economy is knowledge-based and a major 
engine for regional economic growth with clusters of biotechnology 
companies.  The pharmaceutical-biotechnology regional and sectoral 
innovation system is characterized as an international and dynamic 
network architecture involving numerous players engaged in drug 
discovery.   The biotechnology industry typically develops within an 
international network involving universities, research institutions, 
incubators, new biotechnology firms and global pharmaceutical 
companies.    
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It is “a complex network of corporate players, dominated by large firms 
with strong marketing capabilities and start-up firms that focus on research 
and development” (Pereira, 2006).   New biotechnology firms partner with 
large pharmaceutical companies to advance the potential of their lead 
product(s) due to lack of infrastructure for late-stage clinical trials and/or 
marketing resources and the need for external investment. 
 
The biotechnology industry faces a high-cost research and development, 
limited commercialization and constant technological change.   The 
industry is characterized by a dynamic combination of the following 
features (Segers, 2017): 
 
• geographical proximity (clustering); 
• the translation of innovative (academic) research into potential drugs; 
• limited commercialization: firms years away from actually marketing a 
drug; 
• High risk – capital-intensive (declining expected return on R&D);  
• a strong science base: a value chain with  a long cycle of product 
development and many technical uncertainties; 
• heavy dependence on patents (patent legislation) and intellectual 
property rights; 
• big Pharma constantly in need of drug candidates to replace expired 
patents and failed projects; 
• new biotechnology firms in need of adequate financing for expensive 
clinical trials and the marketing channels of big pharmaceuticals; 
• external partnerships versus in-house efforts to generate innovative 
medicines and create new value; 
• large firms using  small firms as a window on leading-edge 
technological developments, not doing the expensive research 
themselves; 
• trade-off between interfirm cooperation (strategic alliances) and 
vertical integration (from discovery to manufacturing and 
marketing/sales); 
• clear institutional and regulatory frameworks;  
• heavy regulation of drugs by governments and healthcare systems 
through approval processes and price controls (Rugman, 2005); 
• different health systems in different countries; 
• ethical clearance mandatory; 
• aging population demanding improved healthcare; 
• growing attention for open innovation and/or open source. 
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Typology of business models 
 
As Pisano (2006; 2007) argued, biotechnology needs a variety of business 
models.  Pisano (2006) distinguishes between “types of pharmaceutical 
innovations which call for vertical integration and which call for alliance-
building and R&D outsourcing”.   According to Fisken and Rutherford 
(2002), “for a biotechnology company, the business model serves to secure 
value from the company’s proprietary technology and know-how and is 
currently often heavily reliant on large (bio)pharmaceutical or established 
biotechnology company customers, collaborators and partners”.  Sabatier 
(2010) refers to the “business model portfolio”. 
 
The following section outlines a selection of key business models applied 
in the biotechnology industry - with own research versus outsourced 
research, depending on the therapeutic fields in which a given new 
biotechnology firm or large pharmaceutical company is operating.  The 
focus is on the differences between closed or stand-alone business models 
opposed to open or networked business models. 
 
① Closed business models  
 
The first generation business model – based on blockbuster drugs – was a 
replicable model of vertical integration from research and development to 
marketing.   It is a closed model of innovation, where all the key activities 
are performed inside the four walls of the company (Chesbrough, 2011).    
 
The second generation of biotechnology startups focused on early stage 
research and collaborated – through alliances – with established 
pharmaceutical  companies to develop and market the products.   The third 
generation were biotech firms selling access to technology platforms, 
rather than specific therapeutic applications (Pisano, 2006; 2007). 
 
Fisken and Rutherford (2002), Friedman (2010) and Phillips (2016) 
distinguish between the product-based, platform-based and hybrid business 
models – the traditional business models – based on the value chain 
structure of the biotechnology industry.     
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1. Product-based    
 
As a general value creation and capture scheme, the dominant logic of 
the drug industry is product-based (Sabatier et al., 2012).  The product 
business model originates from the pharmaceutical model where value 
is added along the activities of the value chain to deliver a final 
product to market.   
The fully integrated pharmaceutical company (FIPCO) is a form of 
vertical business model focused on developing a pharmaceutical 
product.  The FIPCO might fall under the category of a "producer 
business model" (Phillips, 2016). 
 
It is also referred to as the: 
o fully integrated biopharmaceutical company (FIBCO); 
o fully integrated life science company (FILCO); 
o fully integrated pharmaceutical network (FIPNET).  
The ultimate goal for many biotech companies is to pursue a traditional 
FIPCO structure controlling the value chain for their product offering.  
The traditional model of fully integrated companies covers the whole 
value-creation cycle from discovery through development and 
commercialization.  A large amount of capital is required.  Medicines 
are developed by the company from the point of discovery up to the 
end of clinical trials or up to approval by the regulatory authorities.   
 
However, for dedicated new biotechnology firms, the high risk and high 
cost of developing and commercializing a new product on their own make 
the platform-based and hybrid business models attractive, through multiple 
alliances (interfirm partnerships) with large pharmaceutical companies. 
 
2. Technology Platform-based   
 
The platform business model is a form of horizontal model.   This 
business model generally focuses on the early drug development 
phases (molecule development).  It leverages on licensing technologies 
to downstream firms.   The model is based on the development of 
research tools or platform technology that can provide a service to 
another organization or can be licensed for further development along 
the value chain, through co-development partnerships.   
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With this business model, companies develop a set of tools or 
integrated technologies and license them out.   Revenue can be 
generated relatively quickly through contract research and services. 
This business model reduces risk and the need for venture capital. 
 
Alternatively, Thong (2015)  refers to the so-called “bioscience 
platform companies”, whose business model includes scientific core 
competencies that are deployed to enable the generation of a 
succession of new therapeutic or diagnostic product candidates. 
Such a company is often centered around a branded proprietary 
technology.   According to Thong (2016), discovery platform 
technology companies are a natural fit with the partnering-centric 
approach.  Over time, platform companies evolve into hybrid 
companies. 
 
3. Hybrid business model 
 
This is a hybrid of the product-based and platform-based business 
models.   Technology platforms are combined with services and the 
generation of a pipeline of products.    
 
The hybrid business model involves identifying internally new 
potential applications of the technology/discovery platform.  New 
biotechnology firms share their technologies with other companies via 
partnerships (strategic alliances) and develop their own proprietary 
projects, to be eventually brought to market in partnership with 
commercial collaborators.   The pipeline of products can be developed 
organically or through additional in-licensing or purchasing access to 
another’s technology.   
 
The hybrid model is the preferred business model for new and existing 
biotechnology companies - particularly by platform or tool-based 
companies - to maintain growth.   They enjoy stable revenues from 
licensing or sales, which allows for attracting investors or using their 
own income stream to develop products.  Investors benefit from 
reduced risks and the possibility of near-term revenue generation.    
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Figure I summarizes the traditional business models in the biotechnology 
industry. 
 
 
Figure I – Traditional business models (Thong, 2015 – adapted) 
 
 
4. Royalty Income Pharmaceutical Company model (RIPCO) 
With limited financial resources, the vast majority of new biotech-
nology firms start out as RIPCOs – research intensive or royalty 
income pharmaceutical companies.   The RIPCO model covers 
platform and tool-based companies seeking to commercialize drug 
targets, services and technologies that can be sold or licensed to other 
companies.  They focus on the earlier stages in the value chain, such as 
discovery and preclinical development.   They research and develop 
new drugs, which they eventually license to a big pharmaceutical 
company in exchange for a royalty on sales.  The large company 
finishes the research, produces the drug and commercializes it.  
 
5. No Research-Development Only model 
The no research - development only model is a derivative of the 
specialty pharmaceutical model.  In this model, new biotechnology 
firms buy or in-license a promising ‘discarded’ drug from large 
pharmaceutical companies.  They complete the late-stage clinical trials, 
bring it to market and try to make it profitable.  
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6. Pure licensing business model 
This model leverages on strong intellectual property rights that are 
licensed to other firms.   The licensors retain ownership of their 
licensed assets.  These are often new biotechnology firms, hampered 
by their lack of financial resources and often unable to develop the 
final products by themselves.  Their business model is to operate in the 
first phases of the value chain, generating revenues in the form of 
licensing payments, while licensees choose to rely partially or 
extensively on these upstream licensors to capture innovation.   Part of 
the value in the pure licensing business model is lost to other firms. 
 
7. Research service companies 
These companies specialize in a specific niche in the value chain.  
They are Contract Research Organizations (CROs) that support pre-
clinical and clinical trials or Contract Manufacturing Organizations 
(CMOs) that specialize in biological products and chemical drugs.   
The panorama of service companies connected to red biotech is very 
wide. 
 
Some new biotechnology firms operate a hybrid model via both 
service/technology provision by strategically selected CROs and  
co-discovery alliances. 
 
8. The IPO (Initial Public Offering) financing model  
Most new biotechnology firms earn no money.   They cannot be valued 
on the basis of earnings.   Their value depends almost exclusively on 
their ongoing R&D projects and on the interpretation of publicly 
announced results of clinical trials.  Deal and licensing information is 
commercially sensitive (Deloitte, 2016). 
 
Pisano (2006) argues that this publicly held model will work only for 
companies that have earnings, allowing investors to judge their 
prospects.  The IPO exit strategy is increasingly limited by the lack of 
product revenues. 
 
Table I illustrates the use of closed business models discussed above by a 
selection of Belgian new biotechnology firms.   These illustrative cases 
will be explained further on in this contribution. 
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Table I – Use of Closed Business Models by Belgian firms 
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② Open business models 
 
According to Chesbrough and Brunswicker (2013), establishing new 
partnerships, exploring new technological trends and identifying new 
business opportunities are the leading strategic reasons to engage in open 
innovation.  Chesbrough (2003) defines open innovation as “a paradigm 
that assumes that firms can and should use external ideas as well as 
internal ideas, and internal and external paths to market, as firms look to 
advance their technology”. 
 
Open innovation is an innovation paradigm shift from a closed to an open 
model.  It is the opposite of the conventional (closed), vertically integrated 
research and development model, in which companies rely heavily on 
internal knowledge and resources (Chesbrough et al, 2006; Chesbrough 
(2003; 2006).  To offset the trends of rising development costs and shorter 
product life cycles, companies must experiment with creative ways to open 
their business models by using outside ideas and technologies in internal 
product development and by allowing inside intellectual property to be 
commercialized externally (Chesbrough, 2007). 
 
According to Chesbrough (2003), there is a continuum from fully open to 
fully closed enterprises, with the degree of openness depending upon a 
number of internal and external factors affecting that particular enterprise.   
This includes the reliance on intellectual property (IP) concepts and the 
complex highly regulated environment (Carroll et al., 2017).   
 
According to Carroll et al. (2017), the (bio)pharmaceutical industry has 
been relatively slow to adopt open innovation approaches.   In open 
innovation, companies don’t restrict their drug development activities to 
their own internal compounds.  Instead, they actively scan the external 
environment, from universities and research institutes early on, to startups 
and specialty pharmaceutical companies later on, for possible drug 
candidates that fit their business model (Chesbrough, 2011).  They focus 
on the rights for diseases they serve in their markets, and license to others 
the rights for alternative markets. 
 
Open business models attack the cost side – rising development costs – by 
leveraging external research and development resources and the revenue 
side by licensing technologies or products worldwide.  These models are 
more efficient to show shareholders a return on investments in research 
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and development.  The core of the model resides in that firms should 
leverage innovation outside.  Openness is then mostly a strategy that 
allows rapid access to valued innovation worldwide while reducing 
operating costs and removing supply chain dependencies.   
 
According to Gay (2014), in the open innovation approach, there is a 
greater reliance on connection, collaboration and partnerships for 
innovative success.  She argues that open business models must delve into 
alliance management.  
 
The following open business models are considered.  They include 
different types of extensive collaboration and cooperation, open 
innovation, open access and data sharing. 
 
9.  The open innovation-based R&D model 
 
The increasing need for startups, academic research centers and 
universities to generate their own funding instead of relying on 
government grants and public financing sources will likely drive the 
adoption of open innovation.   The open innovation-based R&D model 
seems to be the way forward for biopharmaceutical companies, as it 
appears to be a more cost- and time-effective way to bring drugs to 
market (Deloitte, 2015a).  In this context, most pharmaceutical 
companies have started to concentrate on their core competencies 
centering around technology platforms and  therapy areas.  They 
switched to streamlining and externalization of (part of) their R&D 
activities (Reepmayer, 2005). 
 
10. Networked business models  
The traditional model of fully integrated companies has evolved 
towards a networked model.   Companies establish collaborations of 
varying intensities – from service providers to co-development partners 
– with large companies, in order to seek out synergies depending on 
their project and stage of development (Biocat, 2009).   According to 
Gay (2014), the recent emphasis on networked business models of big 
pharmaceutical companies and venture capital firms which interact in 
open innovation with small biotech companies reflects that single 
companies cannot possibly master all the significant resources needed 
in R&D, production, and marketing.   By opening their business 
models through economic transactions, companies can be more 
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effective in creating as well as capturing value.  Firms thus leverage 
other companies’ technologies, products, or organizational capabilities 
but also let other organizations leverage their assets. 
 
11. Collaborative discovery business model    
 
This model is similar to the networked business model.  The partner-
ship and joint R&D aspects of these alliances are significant in 
business model innovation terms, since they require new approaches to 
collaboration and property rights ownership where partners, rather than 
addressing the mass product markets, collaborate with individual 
patients in designing one-off personalized or group-specific treatments 
(Sabatier et al., 2012).  This involves collaboration with drug and 
diagnostics companies for discovery of new candidates through 
customization of in-house platforms to meet specifically defined 
customer goals.  Collaborative models have been predicted to be the 
business models of the future, although Gay (2014) points out that the 
question of how profits should be split between partners has not been 
addressed. 
 
12. IP-oriented business models  
 
Intellectual property (IP) rights are of critical value in a knowledge-
based society.  Patent policies are particularly important in 
biotechnology in support of the activity of smaller technology-based 
firms and university licensing.  This aspect is of particular relevance to 
the pharmaceutical industry since the nature and development of 
pharmaceutical products make companies highly dependent on proper 
IP protection and enforcement (European Commission, 2014) and on 
the value created from IP rights.  In the founder-oriented biotech, life 
sciences and pharma industry, patents are what create the value of an 
invention.   The "final product" of drug discovery is a patent on the 
potential drug. 
 
Open innovation is not about abolishing patenting (Holgersson et al., 
2016).   Open IP approaches are emerging through patent portfolios or 
patent pools.  The patents portfolio and other intellectual property 
rights are in need of an entrepreneurial approach in order to provide 
sufficient returns to the individual (new) biotechnology firm. 
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According to Pisano (2006), monetizing IP was seen as the best way to 
finance long-term product development.  This involves financing 
research and innovation through licensing, partnerships, royalties, etc. 
(i.e. asset-based income), but not necessarily through product sales (i.e. 
commodity-based income) (Birch, 2016). 
 
Kerry and Danson (2016) refer to the use of a business model where IP 
protection actually enables companies to collaborate confidently in the 
knowledge that they will be able to enjoy some protection from direct 
imitation by others.   The company portfolio of technologies and 
products is usually sold or licensed out.  A suitable network and 
cooperation strategy is required to ensure the successful commerciali-
zation of the intellectual property.  
 
Stevens et al. (2016) outline the differences between an open 
collaboration intellectual property framework and a partnership 
focused public-private partnership model.  The latter is an investment-
friendly model, as preferred access is a major incentive for industrial 
partners.   West and Olk (2016) investigate how firms reconcile the 
open nature of research and development consortia with their 
traditional IP-based business models. 
 
According to Holgersson et al. (2016), better patent management could 
also incentivize the repositioning of old substances to new diseases 
(abandoned compounds for rare and uncommon diseases) through the 
application of method of use patents or formulation patents.  The 
method of use patent extends the protection time of the chemical 
substance for that specific use. 
 
13. The virtual R&D model   
 
This is not a common model.  The virtual R&D-model has emerged in 
the biotechnology industry, where small groups of scientists discover 
and develop a new drug candidate with the help of external resources 
(Schuhmacher et al.,  2013; PwC, 2010).  According to Sabatier et al. 
(2010), the business logic and source of value of this model are in 
orchestrating a network to develop drug products.  Virtual firms 
depend entirely on their partner alliances for access to knowledge, 
equipment and markets. 
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A virtual biotech company is basically a drug development company 
with an extensive development pipeline of candidate molecules, but 
with no employees.  All the development is contracted with a contract 
research organization.  The available capital is directly invested in drug 
discovery and development (Labiotech, 2017). 
 
Dixon (2011) refers to the Virtually Integrated Pharmaceutical 
Company Organisation (VIPCO).   This is a business model, 
whereby companies may outsource/contract extensively for 
services at any point(s) in the value chain, providing access to 
complementary assets outside the firm. This allows a company to 
maintain control of the product development process and defer the 
point at which they plug into the value chain. 
 
Shire has implemented elements of an open, virtual and partnership-
oriented concept: an open, collaborative and networked R&D model 
of ‘early alliance’ whereby pharmaceutical and biotechnology 
companies collaborate in early R&D.   The biotechnology company 
provides the innovation, whereas the pharmaceutical partner 
contributes its capacities to discover and develop jointly an early 
drug candidate with the purpose of having access to the drug 
project later.  Alternatively, it can use the early alliance to 
familiarize with a new technology or therapeutic area without 
investing too many resources (Schuhmacher et al.,  2013). 
 
According to Thong (2016) virtual biotechs are inevitably acquired 
quickly by large companies if their projects are successful. 
 
14. Patient-centricity 
 
Patient-centricity is an evolving and increasingly important element of 
the pharmaceutical  business model, as governments and healthcare 
providers move toward a healthcare system that focuses on outcomes 
rather than on products and services.   Reimbursement and pricing 
reflect the trend towards cost efficiency of healthcare systems.  This 
puts increased pressure on the future returns of new biotechnology 
firms and large pharmaceutical companies (PhRMA, 2014; Deloitte, 
2015b). 
 
Aging populations, consumerism, increases in chronic and orphan 
diseases, new medical technologies and treatments (Cotter, 2006) are 
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putting new strains on healthcare systems.  Patients are more aware of 
available treatment options and are demanding choice.   The 
technology-driven ability to leverage health data is enabling providers 
to make better and faster diagnoses – e.g. through bioinformatics and 
open data – as well as more informed treatment decisions. 
 
The old business model based on blockbuster drugs, incremental 
innovation and physician preferences is under pressure by innovative 
patient-centered models (Heidrick and Struggles, 2014; Saias and 
Kapadia, 2016), making the company’s drug development processes 
more patient-centric.  It involves a shift from a product-driven 
approach towards a connected patient-centered healthcare ecosystem.  
The involvement of the patient can be applied at every stage of a 
pharmaceutical company’s efforts, from drug discovery to winning 
regulatory approval to post-market disease management.   
 
Allarakhia (2015) distinguishes a newly devised continuum of patient 
engagement across several models of open innovation: crowd research, 
research partnerships, co-design programs, patient communities and 
focus groups.  It is about engaging patients in open innovation drug 
discovery research, getting patients to rate their treatment needs and to 
translate those needs into drug research properties, which may help 
new biotechnology firms and pharmaceutical companies to find new 
molecules.   
 
Table II illustrates the use of open business models discussed above by 
Belgian new biotechnology firms and Belgian large pharmaceuticals. 
 
 
 
Table II – Use of Open Business Models by Belgian firms 
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Illustrative case analysis and good practices   
 
Segers (2017) provided a longitudinal follow up (i.e. 1987-2017) of 30 
Belgian new biotechnology firms in the bioRegions of Flanders and 
Wallonia in his country study for the biotechnology industry in Belgium.  A 
number of illustrative case studies and good practices are taken from that 
study to support the hypotheses that new biotechnology firms in Belgium 
apply a mix of the closed and open business models as presented in the 
“typology” section above.  
 
The focus is on red biotechnology, i.e. pharmaceutical and healthcare 
applications.  New biotechnology firms are both beneficiaries and targets 
of strategic partnering alliances with large and global (bio)pharmaceutical 
companies. A number of the Belgian new biotechnology firms hold a 
nodal position as “most preferred partner” with multiple alliances in 
dynamic R&D networks.  Segers (2015; 2016; 2017) found a large number 
of strategic alliances and networks involving interfirm partnering activities 
between large and global (bio)pharmaceutical companies like Johnson & 
Johnson, Pfizer, Novartis, Roche, Merck & Co., Sanofi-Aventis, 
GlaxoSmithKline, AstraZeneca, Eli Lilly and AbbVie amongst others and 
Belgian new biotechnology firms. 
 
The Belgian new biotechnology firms are either still in the preclinical stage 
of therapeutic research, developing targets and compounds in their early 
stages of existence or developing technology platforms in leading edge drug 
development. Most of them conduct research in the discovery phases I 
and/or II. They are involved in interactive collaborations (strategic 
alliances) with big pharmaceuticals, often with a co-creation goal: 
therapeutic targets, finding new molecules with a blockbuster potential, 
transforming the new molecule into a commercial drug. 
 
Belgian new biotechnology firms apply a business model portfolio strategy 
to capture value from the proprietary technology and know-how, given the 
high risk and high cost of developing and commercializing a new product 
on their own. They have a high degree of  dependence on milestone and 
success payments in the early stages of development.  The business models 
most used are the technology platform model, the hybrid model, the royalty 
income model, the pure licensing model, the IPO financing model and the 
research services model. 
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The following illustrative cases and good practices are taken from the Segers 
(2017) country study on the biotechnology industry in Belgium. All case 
firms (CF) are either listed Euronext Stock Exchange (Brussels – Paris – 
Amsterdam) and have launched an initial public offering (IPO).  Argenx, 
Galàpagos and Celyad are also listed on Nasdaq in New York.   
 
CF1: ThromboGenics 
ThromboGenics (THR, founded in 1998) is (was) the “star” amongst the 
biotechnology firms in Belgium.  The company was established as a spin-
off of the University of Leuven (KU Leuven), working on biopharmaceuti-
cal drug development between academia and industry.  The company 
developed over the years from a university spin-off to a fully integrated 
specialty pharmaceutical company, with a promising biotechnology-based 
pipeline.  Its primary goals are to develop and commercialize innovative 
therapies in ophthalmology (visual disorders, with a special focus on 
diabetes, i.e. diabetic retinopathy), cardiovascular diseases and oncology 
(cancer).   Over the years, ThromboGenics partnered in a large number of 
strategic alliances with major players in global biotechnology.  These 
strategic partnerships include research collaborations, co-development and 
co-commercialization as well as in-licensing agreements. 
 
ThromboGenics lead product JETREA (ocriplasmin-platform; back of the 
eye disease) was approved by the Food and Drug Administration (FDA) in 
October 2012 for symptomatic vitreomacular adhesion (VMA) in the eyes 
and subsequently launched in January 2013.   In March 2012, 
ThromboGenics signed a strategic partnership with Alcon (Novartis).  
Novartis' ophthalmic unit Alcon acquired the non-US rights to ocriplasmin, 
giving ThromboGenics access to significant milestone payments and 
royalties.  ThromboGenics experienced problems with its commercial 
organization supporting JETREA and hence a downturn of its US-sales, 
which amounted to a lower than expected market demand of its lead 
product.  
 
From 2013 onwards, ThromboGenics explored new “strategic options” and 
made a turnaround towards the development and commercialization of next 
generation therapies for the treatment of severe diabetic eye disorders.  
ThromboGenics evolved from a university spin-off to a fully integrated 
biopharmaceutical company and is now a clinical stage biotechnology 
company, taking its future prospects beyond its lead product JETREA®. 
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In April 2015, the company’s research and development activities in 
oncology were spun out into a separate entity.  Oncurious is a joint venture 
with the Flanders Institute of Biotechnology, a regional government funded 
institution that focuses on translating basic scientific results into 
pharmaceutical, agricultural and industrial applications.   Oncurious is 
leveraging the joint expertise to develop innovative medicines (orphan 
drugs) for the treatment of pediatric cancer (brain tumors). 
 
In March 2016, ThromboGenics signed a global in-licensing agreement 
(inbound open innovation) with Galapagos with respect to certain 
compounds to develop and commercialize THR-687 for the treatment of 
diabetic eye disease (diabetic retinopathy).   ThromboGenics will pay a 
technology transfer fee to Galapagos.   Galapagos will also be entitled to 
development and commercial milestone payments plus royalties on net 
sales of products. 
 
In september 2017, ThromboGenics regained full global rights to 
JETREA® from Alcon, a Novartis company. 
 
CF2 & CF3: Ablynx and Argenx 
Ghent (Belgium)-based Ablynx and Argenx both develop llama-inspired 
molecules (i.e. the llama immune system).  This technology has led to 
collaborations with multiple pharmaceutical companies including AbbVie, 
Boehringer Ingelheim, Merck & Co., Merck KGaA, Novartis, Novo 
Nordisk, Shire, Bayer and Sanofi. 
They adopt a “best of both worlds” strategy (Thong, 2015) that involves 
spinning off single asset entities for commercialization and marketing, 
while retaining the platform core in the original mother company. 
 
Argenx is a clinical-stage biotechnology company developing a 
pipeline of antibody-based therapies for the treatment of severe 
autoimmune diseases and cancer (immuno-oncology).  The Argenx-case 
(Figure II) is a good example of a business model portfolio 
maximizing shareholder value.  Argenx captures value at different 
stages through: 
 
• platform deals with Shire and Bayer in the discovery stage via 
the SIMPLE antibody platform; 
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• product deals and thriving strategic alliances with Bird Rock 
Bio, LEO Pharma and AbbVie; 
• wholly owned antibodies in early & late clinical development; 
• research collaborations through Argenx’s Innovative Access 
Program. 
 
 
 
Figure II – Argenx (De Tijd - Finance Avenue, 2016) - adapted 
Ablynx is a biopharmaceutical company which is developing single 
domain antibodies derived from llamas for various diseases.  Ablynx is 
developing several proprietary programs in various therapeutic areas 
including inflammation, haematology, immuno-oncology, oncology and 
respiratory disease.  Its lead - wholly-owned - candidate Caplacizumab, 
has been submitted for a marketing authorisation to the European 
Medicines Agency for approval in the treatment of acquired thrombotic 
thrombocytopenic purpura (aTTP).  
CF4: Galàpagos 
Galàpagos on the other hand is capturing value in a very competitive 
landscape from a mix of top-level partnerships with a number of big 
pharmaceuticals for clinical trials on multiple indications of its lead 
products, as Figure III shows.   
 
Galàpagos discovered and developed filgotinib for the treatment of 
rheumatoid arthritis.  The Belgian new biotechnology firm entered into a 
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strategic alliance with Gilead Sciences, following an earlier surprise 
decision by AbbVie not to opt into filgotinib’s development. 
 
With respect to the strategic alliances portfolio and the product pipeline, 
Galàpagos is currently the most likely to make it to the fully integrated 
pharmaceutical company (FIPCO) model stage (Segers, 2017). 
 
 
 
 
 
Figure III – Galàpagos’ pipeline (labiotech.eu, 2016) 
 
CF5: Celyad 
Celyad is a clinical-stage biopharmaceutical company, specialized in cell 
therapy.  It is looking for a pharmaceutical partner to further develop and 
commercialize its lead cardiology candidate, C-Cure.  In addition, Celyad is 
focusing on its CAR-T pipeline, including its allogeneic NKR-2 T-cell 
immunotherapy.    
 
The company announced a non-exclusive license agreement with Novartis 
for Celyad’s US patents for the production of allogeneic CAR-T cells.  This 
license agreement is related to two targets currently under development by 
Novartis. 
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A lot of attention in recent literature is directed towards the analysis of  good 
practices on open innovation approaches. These approaches are developed 
with an emphasis on the emerging collaborative models that have shown a 
certain level of success. Segers (2017) found that Belgian new 
biotechnology firms are able to adopt innovative business models by 
providing R&D and services to larger firms and openly cooperating with 
them through open innovation.   
 
The open business models most used are: 
 
• the open innovation-based research and development model; 
• the networked model; 
• collaborative discovery. 
 
Four illustrative good practices (GP) are presented below. 
 
GP1: Janssen (J&J) 
 
Janssen Pharmaceuticals (part of Johnson & Johnson) set up a regionally 
embedded innovation ecosystem (Robaczewska et al, 2016).  This is an 
example of a collaborative model where Johnson & Johnson created 
regional clusters of life sciences start-ups and innovation hubs.   
 
Johnson & Johnson (2015) launched its Janssen Labs (JLABS) network of 
biotechnology/life sciences incubators in San Diego, San Francisco, 
Boston, Toronto, Shanghai and London. The innovation hubs provide life 
science entrepreneurs and scientists with an open collaboration space 
(Weverbergh, 2013) for early-stage research in developing medical device 
and diagnostic technologies, consumer health care products and 
pharmaceuticals.  
 
This approach enhances sourcing external innovation.  It goes beyond the 
traditional focus of open innovation as Johnson & Johnson/Janssen try to 
leverage external talent and expertise, share public infrastructure, raise 
funding and influence public policies.  The incubated life science start-ups 
are granted access to J&J’s compound library and to its regulatory and 
commercial experts.  Researchers working within the J&J-facilities do not 
work for Johnson & Johnson.  Nor do their discoveries belong to J&J.   
Some of them even receive funding from J&J’s competitors, such as 
Novartis, Pfizer and Bristol Myers Squibb (Fortune, 2016).  Johnson & 
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Johnson/Janssen Pharmaceuticals gain access to some valuable 
technology, scientific talents and entrepreneurs in the life sciences space in 
backing these startups and set up development collaborations that help 
accelerate their growth.    
    
Building on this growing JLABS network, Johnson & Johnson (2016) 
opened JLINX at its Janssen Pharmaceuticals Campus in Beerse 
(Belgium).   JLINX will focus on innovation in pharma and cross-
disciplinary healthcare solutions (FierceBiotech, 2016).   Janssen 
Healthcare Innovation (Davies, 2016) is investing heavily in patient 
support programs.   Patients are increasingly provided with the opportunity 
to participate in decisions relating to their healthcare. 
 
Janssen (2017) also established the Integrated Smart Trial & Engagement 
Platform (iSTEP), a patient engagement mobile platform that can track 
medication adherence: "The open innovation philosophy at Janssen led us 
to develop iSTEP in a way that allows the technology to be available to 
other pharmaceutical companies. We believe that having a consistent 
approach across the industry can accelerate the process of bringing 
medicines to patients”.    
 
GP2: Biocartis Idylla platform 
 
The Belgian new biotechnology firm Biocartis (Mechelen, Flanders 
bioRegion) is active in molecular diagnostics, rapid cancer and virus tests.   
Biocartis is opening up its Idylla-platform for external developers and is 
working together with Janssen Diagnostics (Johnson & Johnson) and Abbott 
Molecular. The Evalution open architecture platform of MyCartis – a 
spinout/division of Biocartis – enables MyCartis to engage in a strong 
industrial partnership with almost any company active in the field of bio-
assay development. 
 
GP3: ThromboGenics/Galàpagos alliance 
 
In March 2016, ThromboGenics signed a global in-licensing agreement 
(inbound open innovation) with Galapagos with respect to certain 
compounds to develop and commercialize THR-687 for the treatment of 
diabetic eye disease (diabetic retinopathy).   ThromboGenics will pay a 
technology transfer fee to Galapagos.   Galapagos will also be entitled to 
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development and commercial milestone payments plus royalties on net 
sales of products. 
 
GP4: UCB Pharma 
 
UCB is a Belgian (Brussels) multinational global (bio)pharmaceutical 
company.   Over the years, it transformed from an original chemical group 
into a pure biopharma company, partnering in a large number of strategic 
alliances.   Its main focus is on neurology and immunology conditions.  
UCB has a number of blockbuster products in its old (Zyrtec, Keppra) and 
new product pipeline (Cimzia, Vimpat, Neupro, Briviact, Evenity).  
 
According to Pop et al. (2017), UCB Pharma’s transition from product 
centricity to patient centricity and a patient-centric service ecosystem was 
triggered by the increased competition and a new internal sense of 
purpose.   Pop et al. (2017) point a the “patient value strategy” that was 
installed from 2015 onwards.   Value is created both for the patient as for 
the organization.  UCB is committed to setting up patient communities.  
 
UCB Pharma gradually transformed from a closed company to  more open 
and collaborative one.  It builts its IP through own R&D or by buying 
other companies, the latter by acquiring Celltech (UK) and Schwarz 
Pharma (Germany). 
 
According to Pop et al. (2017), UCB is slowly embracing open innovation 
to find new and improved medicines and treatments for millions of 
patients worldwide.   The Technology Platform Access Program allows 
partners to access UCB’s state-of-the-art technology and to collaborate 
with the R&D department to discover new drugs.  
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Discussion and Conclusions 
 
Several business models exist in the biotechnology industry.   New and 
disruptive models have emerged.   They do not necessarily replace the 
older traditional ones.  The typology of biotechnology business models in 
this contribution shows that new biotechnology firms and large global 
pharmaceutical companies both develop new open business models that 
compete against or work in symbiosis with traditional closed business 
models. 
 
The illustrative case studies and good practices for Belgium show that new 
biotechnology firms in Belgium are gradually adopting a “best of both 
worlds” strategy, with both closed business models and open, networked 
models as a way for gaining access to the market, in close collaboration 
with the large global pharmaceutical companies. 
Table III summarizes the business models most used by the Belgian firms. 
 
 
 
Table III – Applicable Business Models 
 
 
The biotechnology industry is clearly looking for new business models that 
can accommodate the shift from a product-driven approach towards a 
connected patient-centered healthcare ecosystem where open business 
models predominate, thus making the company’s drug development 
processes more patient-centric. 
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The novel approaches adopted by both Janssen (GP1) and UCB (GP4) are 
“a far cry from the traditional paradigm of pharmaceutical companies 
working in isolation, fiercely protective of their ideas” (Osborne, 2017). 
 
It is therefore fair to conclude that the closed business models based on 
vertical integration, blockbuster drugs and physician preferences are under 
pressure by innovative patient-centered models.    
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